Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Bull Environ Contam Toxicol ; 108(4): 702-707, 2022 Apr.
Article in English | MEDLINE | ID: mdl-34748045

ABSTRACT

Freshwater mussels are used as an effective bioindicator of metal pollution. There is no data on the accumulation of any metal-oxide nanoparticles (NPs) in tissues of Unio tigridis. Thus, this study was undertaken to investigate accumulation of Al2O3, CuO, and TiO2 NPs following exposure to different concentrations (0, 1, 3, and 9 mg/L) of NPs for 14 days. Metal concentrations in tissues were determined by ICP-MS, while NP presence was demonstrated by transmission electron microscope (TEM) images. During the experiments, mussels were fed with cultured algae (Chlorella vulgaris). TEM images demonstrated the presence of NPs in digestive gland and muscle. TEM images also suggested that NPs were taken via the lysosomes or endosomes. Highest mean concentrations (µg/g d.w.) of aluminium (76.51), copper (111.63) and titanium (113.83) occurred in the gills and followed by the digestive glands and muscles. Algae consumption of mussels did not significantly differ among controls and NP-exposed groups.


Subject(s)
Chlorella vulgaris , Metal Nanoparticles , Nanoparticles , Unio , Water Pollutants, Chemical , Animals , Copper , Fresh Water , Titanium
2.
Ultrastruct Pathol ; 45(3): 167-181, 2021 May 04.
Article in English | MEDLINE | ID: mdl-34184615

ABSTRACT

Peripheral nerve injury (PNI) is a major health problem that results in loss of motor and sensory functions. In treatment of PNI, various methods such as anastomosis, nerve grafts, nonneural tissue grafts, and nerve conduits are applied. In the present study, it was aimed to investigate the effects of Theranekron and Alpha-lipoic acid (ALA) combined treatment on nerve healing in experimental PNI by using histomorphometric, electron microscopic, immunohistochemical and molecular biological methods. Sixty-two Wistar rats were divided into six groups; the normal control group, sham operation group, experimental control group having a crush type injury with no treatment, Theranekron treatment group, ALA treatment group and Theranekron+ALA combined treatment group. Sciatic nerve tissue samples were obtained on days 1, 7 and 14 following injury in all groups. GAP-43 expression was upregulated in all PNI received groups compared to the control group. Krox-20 expression was downregulated in all groups that received PNI compared to the control group. While intensely positive TNF-α and IL-6 expressions were observed up to the 1st to the 14th day for the experimental control group, these expressions were seen as "weakly positive" in the treatment groups from the 1st day to the 14th day. The number of myelinated fibers was higher in the control and sham operation groups. Additionally, the number of myelinated nerve fibers increased in the combined treatment group. In conclusion, these findings suggest that combined therapy of Theranekron and ALA promotes structural recovery and it should be considered as an effective treatment protocol following PNI.


Subject(s)
Peripheral Nerve Injuries , Thioctic Acid , Animals , GAP-43 Protein/genetics , Gene Expression , Inflammation , Peripheral Nerve Injuries/drug therapy , Rats , Rats, Wistar , Sciatic Nerve , Spider Venoms , Thioctic Acid/pharmacology
3.
Int Immunopharmacol ; 143(Pt 2): 113439, 2024 Oct 22.
Article in English | MEDLINE | ID: mdl-39442190

ABSTRACT

Rheumatoid arthritis (RA) is a multifactorial autoimmune disease that affects the joints of approximately 1 % of the population worldwide and is seen 2-4 times less in males. INSL3 is a gender-specific peptide hormone produced much higher in males than in females and may have an anti-inflammatory role in RA. So, in this study, it was aimed to determine the possible anti-inflammatory effect and dose of insulin-like factor-3(INSL3) in an experimental Complete Freund's adjuvant(CFA)-induced RA male rat model and lipopolysaccharide(LPS)-induced macrophage cell line and compare it with prednisolone therapy. For in vivo experiments, 48 male mice were randomly divided into 6 groups with 8 subjects in each group: Control group, Arthritis group, Arthritis + Prednisolone(10 mg/kg) group, Arthritis + INSL3(0.08-0.8-8 µg/day) groups. Joint tissue samples obtained from sacrificed subjects were examined by histochemical and immunohistochemically methods after biometric analyses, arthritis severity scoring, and thermal latency experiments. LPS-induced macrophage cells were also treated with prednisolone(1 µg/ml) and INSL3(50-100-200 nM). Cell viability, cell morphology, and TNF-α and IL-6 immune reactivity were evaluated. According to the data obtained from in vivo analyses, it was seen that INSL3 reduced the paw diameter and arthritis severity scoring, degenerative changes, and inflammation and increased the thermal latency, compared to the arthritis group, although not as much as the prednisolone treatment group. In vitro analyses showed that high doses of INSL3 had positive effects on cell viability, morphology, TNF-α, and IL-6 immune reactivity. In conclusion, it was determined that the anti-inflammatory effect of INSL3 was not as pronounced as prednisolone, but it had a more favorable impact on macrophage cell viability and morphology. It was concluded that INSL3 may be a protective therapeutic agent in combination with existing treatment protocols in treating many autoimmune diseases.

4.
J Diabetes Res ; 2023: 6657869, 2023.
Article in English | MEDLINE | ID: mdl-38020198

ABSTRACT

Results: Our findings suggest that antioxidants and PMF may alleviate impaired protein synthesis and degradation pathways in skeletal muscle atrophy. PTS showed a positive effect on the anabolic pathway, while RSV and PMF demonstrated potential for ameliorating the catabolic pathway. Notably, the combination therapy of antioxidants and PMF exhibited a stronger ameliorative effect on skeletal muscle atrophy than either intervention alone. Conclusion: The present results highlight the benefits of employing a multimodal approach, involving both antioxidant and PMF therapy, for the management of muscle-wasting conditions. These treatments may have potential therapeutic implications for skeletal muscle atrophy.


Subject(s)
Antioxidants , Muscular Atrophy , Humans , Antioxidants/pharmacology , Antioxidants/therapeutic use , Antioxidants/metabolism , Streptozocin/pharmacology , Muscular Atrophy/prevention & control , Muscle, Skeletal/metabolism , Magnetic Fields
SELECTION OF CITATIONS
SEARCH DETAIL